Jeffrey S. Farrow - 24 Apr 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Financial Officer and Chief Strategic Officer
Signature
/s/ Jeffrey Farrow
Issuer symbol
TARS
Transactions as of
24 Apr 2023
Net transactions value
$0
Form type
4
Filing time
26 Apr 2023, 17:05:03 UTC
Previous filing
06 Oct 2022
Next filing
11 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +163,397 $0.000000 163,397 24 Apr 2023 Common Stock 163,397 $14.62 Direct F1
transaction TARS Restricted Stock Units Award $0 +111,525 $0.000000 111,525 24 Apr 2023 Common Stock 111,525 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest on April 24, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service.

Remarks:

Chief Financial Officer and Chief Strategic Officer